NCT01716416View on ClinicalTrials.gov

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2017

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Pazopanib

DRUG

Cetuximab

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Washington University School of Medicine

OTHER